CoChat

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells

Open access
Wang, Zilu, Hu, Huimin, Heitink, Luuk, Rogers, Kelly, You, Yue, Tan, Tao, Suen, Connie Li Wai, Garnham, Alex, Chen, Hao, Lieschke, Elizabeth, Diepstraten, Sarah T., Chang, Catherine, Chen, Tianwei, Moujalled, Diane, Sutherland, Kate, Lessene, Guillaume, Sieber, Oliver M., Visvader, Jane, Kelly, Gemma L., Strasser, Andreas · 2023 · Cell Death & Differentiation
Cited by 46

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Mutant TP53 proteins are thought to drive the development and sustained expansion of cancers at least in part through the loss of the wild-type (wt) TP53 tumour suppressive functions. Therefore, compounds that can restore wt TP53 functions in mutant TP53 proteins are expected to inhibit the expansion of tumours expressing mutant TP53. APR-246 has been reported to exert such effects in malignant cells and is currently undergoing clinical trials in several cancer types. However, there is evidence that APR-246 may also kill malignant cells that do not express mutant TP53. To support the clinical development of APR-246 it is important to understand its mechanism(s) of action. By establishing isogenic background tumour cell lines with different TP53/TRP53 states, we found that APR-246 can kill malignant cells irrespective of their TP53/TRP53 status. Accordingly, RNAseq analysis revealed that treatment with APR-246 induces expression of the same gene set in Eμ-Myc mouse lymphoma cells of all four possible TRP53 states, wt, wt alongside mutant, knockout and knockout alongside mutant. We found that depending on the type of cancer cell and the concentration of APR-246 used, this compound can kill malignant cells through induction of various programmed cell death pathways, including apoptosis, necroptosis and ferroptosis. The sensitivity of non-transformed cells to APR-246 also depended on the cell type. These findings reveal that the clinical testing of APR-246 should not be limited to cancers expressing mutant TP53 but expanded to cancers that express wt TP53 or are TP53-deficient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41418-023-01122-3

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Metadata

Authors
Wang, Z., Hu, H., Heitink, L., Rogers, K., You, Y., Tan, T., Suen, C. L. W., Garnham, A., Chen, H., Lieschke, E., Diepstraten, S. T., Chang, C., Chen, T., Moujalled, D., Sutherland, K., Lessene, G., Sieber, O. M., Visvader, J., Kelly, G. L., & Strasser, A.
Venue
Cell Death & Differentiation
Published
2023-02-04
Volume
30
Issue
4
Pages
1033-1046
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W4319262297
Cited by
46
References
21
FWCI
4.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. https://app.cochat.ai/papers/10.1038/s41418-023-01122-3
The paper
Wang, Z., Hu, H., Heitink, L., Rogers, K., You, Y., Tan, T., Suen, C. L. W., Garnham, A., Chen, H., Lieschke, E., Diepstraten, S. T., Chang, C., Chen, T., Moujalled, D., Sutherland, K., Lessene, G., Sieber, O. M., Visvader, J., Kelly, G. L., & Strasser, A. (2023). The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death & Differentiation. https://doi.org/10.1038/s41418-023-01122-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.